Mission GBM
Subscribe
Sign in
Home
Glossary of Terms
Brain Cancer News
Brain Cancer Science Talk
Clinical Trials
FAQs
Goals of Care
Investing in Brain Cancer
Julie's Journey
Meet the Team
Archive
About
Brain Cancer News
Latest
Top
Breaking News: FDA Approves Vorasidenib (Voranigo®)
A great day for Low Grade Astrocytoma and Oligodendroglioma Patients with IDH1/IDH2 Mutations
Aug 6
•
Scott L. Rakestraw, PhD
7
Share this post
Breaking News: FDA Approves Vorasidenib (Voranigo®)
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
ASCO 2024: Brain Cancer Highlights
A few potential gems begin to sparkle
Jun 20
•
Scott L. Rakestraw, PhD
2
Share this post
ASCO 2024: Brain Cancer Highlights
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
News: Erasca Reorganizes and Deprioritizes Development of ERAS-801 for rGBM
Yet Another EGFR-targeted Monotherapy Drops Anchor
May 17
•
Scott L. Rakestraw, PhD
3
Share this post
News: Erasca Reorganizes and Deprioritizes Development of ERAS-801 for rGBM
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
Sam Blackman Speaks from the Heart
A personal account of bringing a new brain cancer medicine to patients
Apr 30
•
Scott L. Rakestraw, PhD
1
Share this post
Sam Blackman Speaks from the Heart
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
Breaking News: FDA Approves Tovorafenib (Ojemda®) for Pediatric LGG with BRAF Mutations
A Wonderful Day for pLGG patients and their families
Apr 23
•
Scott L. Rakestraw, PhD
5
Share this post
Breaking News: FDA Approves Tovorafenib (Ojemda®) for Pediatric LGG with BRAF Mutations
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
AACR Brain Cancer Highlights
A tantalizing Phase 1 study of AZD-1390, some potential insights into poor CAR-T efficacy against solid tumors, and disappointing OS performance of…
Apr 11
•
Scott L. Rakestraw, PhD
2
Share this post
AACR Brain Cancer Highlights
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
Marizomib Fails a Phase 3 Clinical Trial in ndGBM Patients
Big Study. Muddy Biology. Ugh!
Mar 29
•
Scott L. Rakestraw, PhD
1
Share this post
Marizomib Fails a Phase 3 Clinical Trial in ndGBM Patients
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
Novocure Reports METIS Top Line Clinical Trial Results for Brain Metastases from NSCLC
Promising, but we will wait for the full data presentation
Mar 27
•
Scott L. Rakestraw, PhD
2
Share this post
Novocure Reports METIS Top Line Clinical Trial Results for Brain Metastases from NSCLC
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant Diffuse Glioma
News of Enormous Potential for IDH-mutant Glioma Patients
Feb 21
•
Scott L. Rakestraw, PhD
6
Share this post
FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant Diffuse Glioma
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
Another EGFRvIII-targeted Program BiTEs the Dust
Same As It Ever Was
Feb 1
•
Scott L. Rakestraw, PhD
2
Share this post
Another EGFRvIII-targeted Program BiTEs the Dust
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
MimiVax Announces New Investments to Support Clinical Development of SurVaxM in Glioblastoma
Example of a transitional model for financing brain cancer therapeutics development
Jan 10
•
Scott L. Rakestraw, PhD
2
Share this post
MimiVax Announces New Investments to Support Clinical Development of SurVaxM in Glioblastoma
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
SNO Storm: Phase 3 Results for DCVax-L
Highlights from the Society for Neuro-Oncology (SNO) 2022 Annual Meeting
Nov 18, 2022
•
Scott L. Rakestraw, PhD
5
Share this post
SNO Storm: Phase 3 Results for DCVax-L
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
Share
Copy link
Facebook
Email
Note
Other
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts